Cushings Syndrome Market Forecasts 2018 - Market Trends, Size, Demand, Cost, Opportunity Analysis and Forecasts to 2018

shanecgordon33

Market Research Store estimates that the 2013 sales for the Cushing's syndrome (CS) therapeutic market was approximately $179m across the 6MM covered in this report. Pharmaceutical and biotechnology companies that are investing their attention, time, and financial resources in the CS field, have adopted a myriad of research and development (R&D) strategies. One notable example is the fact that drug developers are focused on developing superior, next-generation inhibitors of cortisol synthesis in the adrenal glands. Steroidogenesis inhibitors were responsible for approximately 28% of total drug sales in the 6MM in 2013, equating to around $50m. As a consequence of this trend, GlobalData expects overall revenues generated by this drug class to increase by approximately 390% to reach around $247m, encompassing 49% of total drug sales in the 6MM in 2018. The expansion in this segment of the CS market is fuelled by the introduction of premium-priced pharmacological agents such as Novartis' LCI699 and Cortendo AB's NormoCort (COR-003) in the US, as well as the arrival of HRA Pharma's Ketoconazole HRA (ketoconazole) to the European CS stage. One of the greatest unmet needs in this indication is a lack of effective drugs directed against the underlying cause of Cushing's disease (the pituitary tumor). Despite this demand, pharmaceutical companies are continuing to adopt a strategy that simply targets the adrenal glands. As a result, there is a vast amount of room for new or existing players to penetrate the market and capture considerable patient share.

Read Complete Report with TOC:
http://www.marketresearchstore.com/report/opportunityanalyzer-cushings-syndrome-opportunity-analysis-and-forecasts-12416

Market Research Store

Cushings Syndrome Market

Size, Share, Global Trends,

Analysis, Research Report

and Forecast,

2014-2019

www.marketresearchstore.com

sales@marketresearchstore.com


Table of content

Report Description

Market Research Store estimates that the 2013 sales for the Cushing's syndrome

(CS) therapeutic market was approximately $179m across the 6MM covered in

this report. Pharmaceutical and biotechnology companies that are investing their

attention, time, and financial resources in the CS field, have adopted a myriad of

research and development (R&D) strategies. One notable example is the fact that

drug developers are focused on developing superior, next-generation inhibitors of

cortisol synthesis in the adrenal glands. Steroidogenesis inhibitors were

responsible for approximately 28% of total drug sales in the 6MM in 2013,

equating to around $50m. As a consequence of this trend, GlobalData expects

overall revenues generated by this drug class to increase by approximately 390%

to reach around $247m, encompassing 49% of total drug sales in the 6MM in

2018.


Table of content

Report Description

The expansion in this segment of the CS market is fuelled by the introduction of

premium-priced pharmacological agents such as Novartis' LCI699 and Cortendo

AB's NormoCort (COR-003) in the US, as well as the arrival of HRA Pharma's

Ketoconazole HRA (ketoconazole) to the European CS stage. One of the greatest

unmet needs in this indication is a lack of effective drugs directed against the

underlying cause of Cushing's disease (the pituitary tumor). Despite this demand,

pharmaceutical companies are continuing to adopt a strategy that simply targets

the adrenal glands. As a result, there is a vast amount of room for new or existing

players to penetrate the market and capture considerable patient share.

Visit Complete Report @

http://www.marketresearchstore.com/report/opportunityanalyzer-cushingssyndrome-opportunity-analysis-and-forecasts-12416

Request For Sample @

http://www.marketresearchstore.com/report/opportunityanalyzer-cushingssyndrome-opportunity-analysis-and-forecasts-12416#requestSample


Table of content

Report Description

Highlights

Key Questions Answered

Although the current standard of care (ketoconazole) is cheap and reasonably

effective in most CS patients, it possesses worrying safety profiles, inconvenient

dosing schedules, is difficult to obtain and can display waning efficacy over time.

Newer medical treatments, for example, Novartis' Signifor (pasireotide) and

Corcept Therapeutics' Korlym (mifepristone) address only some of these issues;

yet, present their own limitations. The CS market is still marked by the existence

of a multitude of unmet needs. What are the main unmet needs in this market?

Will the drugs under development fulfil the unmet needs of the CS market?

The late-stage CS pipeline is sparsely populated; however, those drugs in

development will be a strong driver of CS market growth. Which of these drugs

will attain high sales revenues during 2013-2018? Which of these drugs will have

the highest peak sales at the highest CAGR, and why?


Table of content

Report Description

Key Findings

One of the main drivers influencing growth in the Cushing's syndrome market will

be the introduction of second-generation steroidogenesis inhibitors, LCI699 and

NormoCort (COR-003), in the US, which will rival existing standard of care medical

treatments.

Another strong driver will be the arrival of Corcept Therapeutics' Korlym

(mifepristone) and HRA Pharma's Ketoconazole HRA (ketoconazole) to the

European CS market. Both drugs will stimulate significant growth here.

The launch of Novartis' Signifor LAR (pasireotide) in the 6MM will equip physicians

with a less frequently administered formulation of Signifor.

Reasons for inadequate CS treatment include poor physician awareness of the

condition, delayed diagnosis, a lack of efficacious drugs for individuals suffering

from severe hypersecretion, and a shortage of effective medicines targeting the

source of Cushing's disease.

Browse Full Report with TOC @

http://www.marketresearchstore.com/report/opportunityanalyzer-cushingssyndrome-opportunity-analysis-and-forecasts-12416#reportTableOfContent


Table of content

Report Description

Scope

Overview of Cushing's syndrome, including epidemiology, etiology,

pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized Cushing's syndrome therapeutics market revenues, annual

cost of therapies and treatment usage pattern data from 2013 and forecast for

five years to 2018. Key topics covered include strategic competitor assessment,

market characterization, unmet needs, clinical trial mapping and implications for

the Cushing's syndrome therapeutics market.

Pipeline analysis: comprehensive data split across different phases,

emerging novel trends under development, and detailed analysis of late-stage

pipeline drugs. Analysis of the current and future market competition in the global

Cushing's syndrome therapeutics market. Insightful review of the key industry

drivers, restraints and challenges. Each trend is independently researched to

provide qualitative analysis of its implications.

Request For Sample @

http://www.marketresearchstore.com/report/opportunityanalyzer-cushingssyndrome-opportunity-analysis-and-forecasts-12416#requestSample


Table of content

Report Description

Reasons to buy

Develop and design your in-licensing and out-licensing strategies through a review

of pipeline products and technologies, and by identifying the companies with the

most robust pipeline. Additionally a list of acquisition targets included in the

pipeline product company list. Develop business strategies by understanding the

trends shaping and driving the Cushing's syndrome therapeutics market.

Drive revenues by understanding the key trends, innovative products and

technologies, market segments, and companies likely to impact the Cushing's

syndrome therapeutics market in the future. Formulate effective sales and

marketing strategies by understanding the competitive landscape and by

analysing the performance of various competitors. Identify emerging players with

potentially strong product portfolios and create effective counter-strategies to

gain a competitive advantage. Track drug sales in the 6MM Cushing's syndrome

therapeutics market from 2013-2018.

Organize your sales and marketing efforts by identifying the market categories and

segments that present maximum opportunities for consolidations, investments

and strategic partnerships.


About Us

Market Research Store is a single destination for all the industry,

company and country reports. We feature large repository of latest

industry reports, leading and niche company profiles, and market

statistics released by reputed private publishers and public

organizations.

Contact Us

Stay With Us:

TELEPHONE: +1-386-310-3803

E-MAIL:

sales@marketresearchstore.com

Suite #8138, 3422 SW

15 Street,

Deerfield Beach, Florida

33442

United States

More magazines by this user
Similar magazines